Neuraxpharm expands into the Middle East

1 October 2024

Germany-headquartered CNS drug specialist Neuraxpharm Group today announced the launch of Neuraxpharm Middle East to cover the six members of the Gulf Cooperation Council (GCC) – the Kingdom of Saudi Arabia, United Arab Emirates (UAE), Bahrain, Kuwait, Oman and Qatar – as the company continues its international expansion.

Neuraxpharm noted that its move into the Middle East follows the opening of affiliates in Brazil and Mexico in 2023 and adds to the growing list of more than 20 European countries where the company is now established alongside its global network of distributors.

Product range to include Briumvi

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK